Activity of ceftolozane–tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata – SMART United States 2016–2017
Open Access
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 20, 209-213
Abstract
No abstract availableKeywords
Funding Information
- Merck
This publication has 17 references indexed in Scilit:
- Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015–2016Journal of Global Antimicrobial Resistance, 2018
- How to manage Pseudomonas aeruginosa infectionsDrugs in Context, 2018
- Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013–2015The Brazilian Journal of Infectious Diseases, 2017
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)Journal of Antimicrobial Chemotherapy, 2017
- Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014Diagnostic Microbiology and Infectious Disease, 2016
- Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosaChest, 2016
- Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012–2013)Clinical Therapeutics, 2016
- Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumoniaInternational Journal of Antimicrobial Agents, 2015
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative BacilliDrugs, 2013
- Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada—results of the CANWARD 2007–2009 studyDiagnostic Microbiology and Infectious Disease, 2011